Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous tocilizumab in adult patients with refractory myositis
2018-000391-15Phase 2Terminated
- Sponsor
- Azienda USL-IRCCS di Reggio Emilia
- Start
- Feb 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tocilizumab in dermatomyositis (DM), polymyositis (PM) and Myositis, sponsored by Azienda USL-IRCCS di Reggio Emilia. Primary endpoint: IMACS-defined improvement. Started Feb 2018; status: terminated.
02
Drugs
tocilizumab
03
Conditions
dermatomyositis (DM)polymyositis (PM)Myositis
Beyond the preview
Go deeper on 2018-000391-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000391-15.